Patient engagement: Pharma’s strategy for success in the New Health Economy

Pharmaceutical companies are facing new demands from consumers, regulators, insurers and independent groups. Constructive engagement with patients and consumers can form a crucial link between these stakeholders, providing better outcomes and value for pharmaceutical companies

Download report
Download chartpack

Executive summary

To understand how the pharmaceutical industry can position itself to better benefit from patient engagement, PwC’s Health Research Institute (HRI) analyzed recent regulatory changes and surveyed consumers about their willingness to engage with pharmaceutical companies and other healthcare entities. Key findings include:

  • Consumers are taking charge of their health and asking to be more involved in decisions related to their care.
  • Regulators are tailoring regulatory approvals to patients’ tolerance for risk and desire for benefits.
  • The healthcare system at large, and insurers in particular, are asking pharmaceutical companies for more evidence that products produce favorable outcomes.
  • Companies can increase their chances of regulatory and commercial success by proactively engaging with patients and learning more about the day-to-day experiences of living with particular diseases, those patients’ values and needs, and their willingness to assume risks in return for access to new treatments.

Contact us

Kelly Barnes
US Health Industries and Global Health Industries Consulting Leader
Tel: +1 (214) 754 5172

Benjamin Gill
Principal, PwC Health Advisory Services
Tel: +1 (617) 283 2638

Benjamin Isgur
Health Research Institute Leader
Tel: +1 (214) 754 5091

Sean Rooney
Principal, PwC Health Advisory Services
Tel: +1 (646) 471 7470

Follow us